(Yicai Global) Dec. 7 -- The China Food and Drug Administration has required eye drop maker Zhejiang Shapuaisi Pharmaceutical Co. [SHA:603168] to conduct clinical effectiveness tests as soon as possible and compile a report on the results within three years, the regulator said online yesterday.
The company claimed in advertisements that its eye drops are able to prevent and treat cataracts. However, there are no drugs on the market that can cure the disease. Surgery is still the most effective treatment, a Chinese online news outlet reported on Dec. 2.
The adverts claimed that the eye drops play a role in slowing down the exacerbation of cataracts and help maintain eyesight without complications, Shapuaisi Pharma said. The food and drug administration told the company to re-write the marketing materials.
Most cataracts patients are elderly and could miss out on the benefits of surgery as a result of Shapuaisi Pharma’s misleading advertising, the report said. This would increase the risk of an operation and could lead to complications.Keywords: Zhejiang Shapuaisi Pharmaceutical, Cataractx, China Food and Drug Administration, Eye Drops